Dr. Dan Kaufmann
- Sun Sep 22 8:50 AM - 9:30 AM Imperial DTherapeutic Drug Monitoring (TDM) of New Antiepileptic Drugs Undergoing Development
Dan Kaufmann, Ph.D. is currently a post-doctoral fellow in the Anticonvulsant Drug Development (ADD) program where he is characterizing a novel valproic acid amide analogue, sec-butyl propylacetamide (SPD). Dan is characterizing SPD for the treatment of epilepsy, neuropathic and inflammatory pain, and migraine disorders, and evaluating its mechanism of action. He has previously engaged in a structure-activity relationship (SAR) study aimed at identifying novel second generation valproic acid analogues that have potential to become future anticonvulsants and pain relieving drugs with better pharmacokinetic and side effects profile. His research was multidisciplinary starting from chemical synthesis of the compounds, evaluating their anticonvulsant and antinociceptive activity using behavioral animal models and determining the pharmacokinetic parameters of the active compounds while developing bioanalytical assays using a GC/MS apparatus. Dan has previously developed thirty four novel analogues of valproic acid which led to the discovery of several lead compounds. One of them, SPD, shows remarkable activity as an anticonvulsant and an antinociceptive, as well as potential as an anti-migraine compound. Dan is currently attempting to gain insight into SPD’s mechanism of action using electrophysiology techniques such as field potentials recordings and patch clamping.